Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

“The Report Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

About Colorectal Cancer Therapeutics Market

Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer cases. This figure has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles.

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth.

Get Sample copy of this Report @

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations.

The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies. In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients. A therapy that targets mutant BRAF – encorafenib plus binimetinib – is being developed in the pipeline.


The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

– How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?

– What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.

– What are the common targets and mechanisms of action of pipeline therapies?

– Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?

– What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

– How have the late-stage therapies performed in clinical trials?

– How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

– How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?

– How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.

– How do deal frequency and value compare between target families and molecule types?

– What were the terms and conditions of key licensing deals?

View Sample PDF @

Reasons to buy

– Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

– Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

– Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

– Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

– Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

– Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

View Report @

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 10

2.1 Disease Introduction 10

2.2 Epidemiology 10

2.3 Symptoms 12

2.4 Etiology and Pathophysiology 12

2.4.1 Etiology 12

2.4.2 Pathophysiology 13

2.4.3 Biomarkers/Targets of Interest 14

2.5 Diagnosis 15

2.5.1 Digital Rectal Examination 16

2.5.2 Fecal Occult Blood Test 16

2.5.3 Flexible Sigmoidoscopy 16

2.5.4 Colonoscopy 16

2.5.5 Virtual Colonoscopy 17

2.5.6 Double Contrast Barium Enema 17

2.6 Disease Stages 17

2.7 Prognosis 19

2.8 Treatment Guidelines and Options 20

2.8.1 Surgery and Radiation Therapy 20

2.8.2 Chemotherapy 21

2.8.3 Targeted Therapies 22

2.8.4 Resistance to Pharmacological Therapies 23

2.8.5 Treatment Algorithm 23

3 Marketed Products 26

3.1 Overview 26

3.2 Chemotherapies 26

3.2.1 Lonsurf (Trifluridine plus Tipiracil) – Taiho Pharma 27

3.2.2 TS-1 (Tegafur plus Gimeracil plus Oteracil) – Taiho Pharma 28

3.2.3 UFT (tegafur plus uracil) – Merck KGaA 29

3.3 Epidermal Growth Factor Receptor Targeted Therapies 29

3.3.1 Erbitux (cetuximab) – Eli Lilly/Merck KGaA 30

3.3.2 Vectibix (panitumumab) – Amgen/Takeda 31

3.4 Anti-angiogenesis Therapies 33

3.4.1 Avastin (bevacizumab) – Roche 33

3.4.2 Cyramza (ramucirumab) – Eli Lilly 35

3.4.3 Zaltrap (Ziv-Aflibercept) – Sanofi/Regeneron 36

3.5 Kinase Inhibitors 37

3.5.1 Stivarga (regorafenib) – Bayer/Onyx 37

3.6 Comparative Efficacy and Safety of Marketed Products 38

4 Pipeline Analysis 40

4.1 Overview 40

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 40

4.3 Pipeline by Molecular Target 43

4.4 Promising Pipeline Candidates 45

4.4.1 Keytruda (pembrolizumab) – Merck & Co. 45

4.4.2 Tecentriq plus Cotellic (Atezolizumab plus cobimetinib) – Roche 47

4.4.3 Napabucasin (BBI-608) – Sumitomo Dainippon Pharma 49

4.4.4 Encorafenib plus binimetinib (LGX-818/MEK-162) – Array BioPharma 50

4.4.5 Masitinib – AB Science 52

4.4.6 Fruquintinib (HMPL-013) – Hutchison MediPharma 54

4.4.7 Famitinib (SHR-1020) – Jiangsu Hengrui Medicine 55

4.4.8 Anlotinib (AL-3818) – Jiangsu Chia-Tai Tianqing 56

4.4.9 Donafenib (CM-4307) – Suzhou Zelgen Biopharmaceuticals 57

4.5 Comparative Efficacy and Safety of Pipeline Products 58

4.6 Product Competitiveness Framework 59

5 Clinical Trial Analysis 61

5.1 Failure Rate 61

5.1.1 Overall Failure Rate 61

5.1.2 Failure Rate by Phase and Molecule Type 62

5.1.3 Failure Rate by Phase and Molecular Target 63

5.2 Clinical Trial Size 64

5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 64

5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 65

5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 66

5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 67

5.3 Clinical Trial Duration 68

5.3.1 Trial Duration by Molecule Type and Stage of Development 68

5.3.2 Trial Duration by Molecular Target and Stage of Development 69

5.4 Summary of Clinical Trial Metrics 70

Send An Enquiry Request @

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074



Designed by
Powered by
%d bloggers like this: